Clinical Trial Update: A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase I study evaluating ZD1839 (gefitinib) with palliative thoracic radiotherapy in patients with non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (Gefitinib) (Gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small-cell Lung Cancer | Phase 1 | Status: COMPLETED